FindTrial
Sign In

PEG-Filgrastim versus Filgrastim as an adjunct to therapy CHOP-14 Rituximab in elderly patients 60-75 years old with B cell non-Hodgkin s High/intermediate grade lymphoma. A randomized, prospectic, multicenter, open-label, phase II study.

PEG-Filgrastim versus Filgrastim as an adjunct to therapy CHOP-14 Rituximab in elderly patients 60-75 years old with B cell non-Hodgkin s High/intermediate grade lymphoma. A randomized, prospectic, multicenter, open-label, phase II study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-004646-13-IT
Enrollment
50
Registered
2007-04-13
Start date
2005-11-17
Completion date
Unknown
Last updated
2013-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maintenance of dose-intensity MedDRA version: 6.1 Level: HLGT Classification code 10025320

Interventions

Trade Name: NEULASTA 6MG 1SIR 0,6ML SC Product Name: Pegfilgrastim Pharmaceutical Form: Solution for injection INN or Proposed INN: Pegfilgrastim Current Sponsor code: 670/05 Concentration unit: mg m

Sponsors

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range ;Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: ;Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s): ;Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Contacts

Public Contact; ;

;

;;

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026